Efficacy of @BioNTech_Group @pfizer BNT162b2 mRNA  in Pts w/ CLL [6/10/21] @herishanu et al @BloodJournal https://t.co/FDK9EzcZ46       @COVID19nCCC Ab response: Remission 79.2%; Tx-naive 55.2%; Active Tx 16.0% https://t.co/GdqDYKoEPC